IP Library Granted Patent US 9,126,981
Granted Patent B2
US 9,126,981 · App. 14/247,105 · Granted Sep 8, 2015

Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions

Inventors: Hiroyuki Kouji (Yokohama, JP); Yuji Kogami (Yokohama, JP); Takenao Odagami (Yokohama, JP)
Assignee: PRISM BioLab Co., Ltd.
C07D409/12C07C271/66C07C275/18C07C311/48C07D213/40C07D215/14C07D277/82C07D309/12C07D333/58C07D401/12C07D487/14C07D487/22C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,126,981
App. No.
14/247,105
Granted
Sep 8, 2015
Kind
B2
Abstract

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Claims (25)

1. A compound having the following general formula (II):

wherein

A is —(CHR 7 )—;

wherein

R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl;

B and E are the same or different and independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl, and wherein B and E do not form an optionally substituted spiro ring indicated by dashed lines;

G is —NH—, —NR 6 —, —O—, —CH 2 —, —CHR 6 — or —C(R 6 ) 2 —;

wherein

each R 6 is the same or different and independently selected from optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;

R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted heterocycloalkylalkyl;

R 2 is —W 21 —W 22 —Rb—R 20 ;

wherein

W 21 is —(CO)— or —(SO 2 )—;

W 22 is bond, —O—, —NH— or optionally substituted lower alkylene;

Rb is bond or optionally substituted lower alkylene; and

R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;

R 91 is selected from optionally substituted alkyl, linker and solid support; and

R 92 is selected from optionally substituted alkyl, linker and solid support;

with the proviso that

1) when Rb is optionally substituted lower alkylene, then W 22 should be —O— or —NH—,

2) when E and B are hydrogen, then R 3 should be hydrogen,

3) when G is —NH—, —CH 2 —, —CHR 6 — or —NR 6 —, then B and E should not be hydrogen, and

4) when G is —O—, B and E are hydrogen and R 3 is hydrogen, then R 1 should not be 8-quinolylmethyl;

or a salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2014
From: PRISM PHARMA CO., LTD.
To: PRISM BIOLAB CO., LTD.
Reel/Frame 033596/0064 →
CHANGE OF NAME Recorded Aug 19, 2014
From: PRISM BIOLAB CORPORATION
To: PRISM PHARMA CO., LTD.
Reel/Frame 033568/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2014
From: KOUJI, HIROYUKI; KOGAMI, YUJI; ODAGAMI, TAKENAO
To: PRISM BIOLAB CORPORATION
Reel/Frame 032621/0014 →
Continuity (3)
Division 13124104
Provisional Application 61105088 · Oct 14, 2008
Related Publication 20140221657A1 · Aug 7, 2014